Matches in SemOpenAlex for { <https://semopenalex.org/work/W4234536242> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4234536242 abstract "<b>Objective</b> <p><a>In the LixiLan-G trial, switching to iGlarLixi, a once-daily titratable fixed-ratio combination of insulin glargine </a>100 units/mL and the glucagon-like peptide-1 receptor agonist (GLP-1 RA) lixisenatide, improved glucose control in type 2 diabetes (T2D) uncontrolled with GLP-1 RAs over 26 weeks versus continuing prior GLP-1 RA. A prespecified, 26-week, single-arm extension of LixiLan-G aimed to determine the durability of iGlarLixi efficacy and safety over 52 weeks. </p> <p><b>Research Design and Methods</b></p> <p>Participants with T2D uncontrolled by GLP-1 RAs (HbA<sub>1c</sub> 7–9 % [53–75 mmol/mol]) were initially randomized to switch to iGlarLixi or continue prior GLP-1 RA. Those randomized to iGlarLixi who completed the 26-week primary endpoint period could continue iGlarLixi open-label treatment over a 26-week extension to assess durability of efficacy and safety.</p> <p><b>Results</b></p> <p>Glycemic control achieved with iGlarLixi at week 26 (mean HbA<sub>1c</sub> 6.7 % [50 mmol/mol]) was maintained at week 52 (mean HbA<sub>1c</sub> 6.7 % [50 mmol/mol]; mean ± standard deviation change from baseline at week 52: −1.0 ± 0.9 % [11 ± 10 mmol/mol]). Proportions of participants reaching HbA<sub>1c</sub> <7 % (53 mmol/mol) with iGlarLixi were similar at week 26 (62%) and 52 (64%), as were those reaching this target without documented symptomatic (<3.0 mmol/L) hypoglycemia (57% and 58%). Safety of iGlarLixi was similar at weeks 26 and 52, with low rates of documented symptomatic hypoglycemia and gastrointestinal events.</p> <p><b>Conclusions</b></p> The efficacy and safety of iGlarLixi at the end of the 26-week randomized treatment period was maintained over the 26-week extension period in the LixiLan-G trial." @default.
- W4234536242 created "2022-05-12" @default.
- W4234536242 creator A5005405894 @default.
- W4234536242 creator A5013839934 @default.
- W4234536242 creator A5019711625 @default.
- W4234536242 creator A5039117287 @default.
- W4234536242 creator A5040943514 @default.
- W4234536242 creator A5045489578 @default.
- W4234536242 creator A5064404279 @default.
- W4234536242 creator A5070289715 @default.
- W4234536242 creator A5086072427 @default.
- W4234536242 date "2021-01-29" @default.
- W4234536242 modified "2023-09-24" @default.
- W4234536242 title "Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study" @default.
- W4234536242 doi "https://doi.org/10.2337/figshare.13369553" @default.
- W4234536242 hasPublicationYear "2021" @default.
- W4234536242 type Work @default.
- W4234536242 citedByCount "0" @default.
- W4234536242 crossrefType "posted-content" @default.
- W4234536242 hasAuthorship W4234536242A5005405894 @default.
- W4234536242 hasAuthorship W4234536242A5013839934 @default.
- W4234536242 hasAuthorship W4234536242A5019711625 @default.
- W4234536242 hasAuthorship W4234536242A5039117287 @default.
- W4234536242 hasAuthorship W4234536242A5040943514 @default.
- W4234536242 hasAuthorship W4234536242A5045489578 @default.
- W4234536242 hasAuthorship W4234536242A5064404279 @default.
- W4234536242 hasAuthorship W4234536242A5070289715 @default.
- W4234536242 hasAuthorship W4234536242A5086072427 @default.
- W4234536242 hasBestOaLocation W42345362421 @default.
- W4234536242 hasConcept C126322002 @default.
- W4234536242 hasConcept C134018914 @default.
- W4234536242 hasConcept C140793950 @default.
- W4234536242 hasConcept C170493617 @default.
- W4234536242 hasConcept C185280430 @default.
- W4234536242 hasConcept C2776442814 @default.
- W4234536242 hasConcept C2777180221 @default.
- W4234536242 hasConcept C2778938600 @default.
- W4234536242 hasConcept C2780473172 @default.
- W4234536242 hasConcept C2780533449 @default.
- W4234536242 hasConcept C555293320 @default.
- W4234536242 hasConcept C71924100 @default.
- W4234536242 hasConcept C86803240 @default.
- W4234536242 hasConceptScore W4234536242C126322002 @default.
- W4234536242 hasConceptScore W4234536242C134018914 @default.
- W4234536242 hasConceptScore W4234536242C140793950 @default.
- W4234536242 hasConceptScore W4234536242C170493617 @default.
- W4234536242 hasConceptScore W4234536242C185280430 @default.
- W4234536242 hasConceptScore W4234536242C2776442814 @default.
- W4234536242 hasConceptScore W4234536242C2777180221 @default.
- W4234536242 hasConceptScore W4234536242C2778938600 @default.
- W4234536242 hasConceptScore W4234536242C2780473172 @default.
- W4234536242 hasConceptScore W4234536242C2780533449 @default.
- W4234536242 hasConceptScore W4234536242C555293320 @default.
- W4234536242 hasConceptScore W4234536242C71924100 @default.
- W4234536242 hasConceptScore W4234536242C86803240 @default.
- W4234536242 hasLocation W42345362421 @default.
- W4234536242 hasLocation W42345362422 @default.
- W4234536242 hasOpenAccess W4234536242 @default.
- W4234536242 hasPrimaryLocation W42345362421 @default.
- W4234536242 hasRelatedWork W14974628 @default.
- W4234536242 hasRelatedWork W15104804 @default.
- W4234536242 hasRelatedWork W15647580 @default.
- W4234536242 hasRelatedWork W15954137 @default.
- W4234536242 hasRelatedWork W1739382 @default.
- W4234536242 hasRelatedWork W18762840 @default.
- W4234536242 hasRelatedWork W20941350 @default.
- W4234536242 hasRelatedWork W7563278 @default.
- W4234536242 hasRelatedWork W7710465 @default.
- W4234536242 hasRelatedWork W8312400 @default.
- W4234536242 isParatext "false" @default.
- W4234536242 isRetracted "false" @default.
- W4234536242 workType "article" @default.